A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally- Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib

Trial Profile

A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally- Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms BRIM-7
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Mar 2017 Planned End Date changed from 1 Dec 2016 to 29 Jun 2018.
    • 11 Oct 2016 Results of an exploratory analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM studies presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top